View Older Stories View More Recent Stories
-
BofA Cautious on Hims and Hers (HIMS): 'HIMS to offer Lilly’s Zepbound, expect minimal revenue contribution'
-
Hims & Hers Health (HIMS) expanding access to personalized weight loss care
-
Hims & Hers Health, Inc. (HIMS) said to sell Lilly's Zepbound
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.7 calls to 1 put
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.1 calls to 1 put amid wide price movement
-
BofA sees 'significant upside' to earnings upside for this popular consumer stock
-
Hims and Hers (HIMS) PT Raised to $22 at BofA Securities, 'execution risk on the top line for a name that has been a beat and raise story since its IPO'
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.2 calls to 1 put amid wide price movement
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS), PT $21
-
Citi Reiterates Sell Rating on Hims and Hers (HIMS), PT $27, 'highly unlikely that this appeal changes much'
-
DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600
-
Hims & Hers Health, Inc. (HIMS) Shares Fall Another 3pct to Levels Last Seen Jan 31
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.3 calls to 1 put
-
Hims & Hers Health, Inc. (HIMS) Trading 50pct Below February High, Down 13pct Today as shares bounce off LOD
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.8 calls to 1 put as share price down 12.5%
-
Citi Reiterates Sell Rating on Hims and Hers (HIMS), PT $27, 'Court Delivers Another Blow to Tirzepatide Compounders'
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS)
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS), PT $21, 'we do not see upside to 2025 revenue guidance'
-
Citi Reiterates Sell Rating on Hims and Hers (HIMS), PT $27, 'We view this as Novo taking a direct shot at HIMS'
-
Hims and Hers (HIMS) PT Raised to $39 at Truist Securities
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1 call to 1.21 puts on 427K contracts
-
Hims and Hers (HIMS) PT Raised to $44 at TD Cowen
-
Hims and Hers (HIMS) PT Raised to $35 at Piper Sandler; 'Wide Range Of Future Outcomes Keeps Us On Sidelines'
-
Hims and Hers (HIMS) PT Raised to $40 at Leerink Partners
-
Hims and Hers (HIMS) PT Raised to $61 at Needham
-
Leerink Partners Reiterates Market Perform Rating on Hims and Hers (HIMS)
-
Morgan Stanley Reiterates Equalweight Rating on Hims and Hers (HIMS)
-
Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS)
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS), PT $21
-
BTIG Reiterates Buy Rating on Hims and Hers (HIMS)
-
Hims and Hers (HIMS) PT Raised to $27 at Citi, Maintains Sell 'as we await a better entry point and more details on growth outside GLP-1s'
-
After-hours movers: Zoom, Hims & Hers Health, Tempus AI, and more
-
Hims & Hers Health, Inc. (HIMS) Misses Q4 EPS by 6c, Revenue Beats, Offers Guidance
-
Hims & Hers earnings preview: BofA weighs in ahead of the report
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1 call to 1.1 puts into quarter results and outlook
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1 call to 1 put on active volume into quarter results
-
Piper Sandler Reiterates Neutral Rating on Hims and Hers (HIMS), PT $24
-
Analysts explain why Hims & Hers stock is crashing today
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.1 calls to 1 put amid wide price movement into quarter results
-
Today's FDA news a 'clear negative' for Hims and Hers (HIMS) - BofA Securities
-
Hims & Hers Health, Inc. (HIMS) Weakness Tied to Report FDA Says Ozempic, Wegovy Shortage Resolved
-
Hims & Hers Health (HIMS) Acquires Peptide Facility
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.2 calls to 1 put into quarter results
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1 call to 1.2 puts on active option volume of 198K contracts
-
Why Morgan Stanley is cautious on Hims & Hers shares
-
Hims and Hers (HIMS) PT Raised to $21 at BofA Securities
-
Hims & Hers Health, Inc. (HIMS) options active on 349K contracts amid sharp rally
-
Hims & Hers Health (HIMS) Acquires At-Home Lab Testing Facility
-
Hims & Hers Health, Inc. (HIMS) options active on volume of 106K contracts amid wide price movement
-
Hims and Hers (HIMS) PT Raised to $68 at Canaccord Genuity

